NEWS & EVENTS 
SPECIALTY CARE
MCT2D Learning Community Event: Updates to the ADA Standards of Care 2026
Updated: 03/23/26
Watch the Recorded Talk
March 19, 2026
In March 2026, the learning community webinar featured Jonathan Gabison, MD, Clinical Assistant Professor of Family Medicine Interim Medical Director, Medical School.
Dr. Jonathan Gabison presented updates to the American Diabetes Association (ADA) guidelines for 2026, focusing on heart failure management, chronic kidney disease, obesity treatment, and other key updates. He discussed the new recommendations for GLP-1 receptor agonists in heart failure with preserved ejection fraction (HEFPEF), particularly highlighting the Summit trial results for terzepatide. The presentation covered updated guidelines for managing non-alcoholic steatohepatitis (NASH) and MASH with GLP-1s, including the ESSENCE trial results showing histological benefits. Dr. Gabison also addressed obesity management strategies, emphasizing slower titration schedules for GLP-1s to improve patient adherence, and discussed the new recommendation for using GLP-1s in type 1 diabetes patients. The session covered updated recommendations for continuous glucose monitoring (CGM) and its broader application beyond insulin-treated patients. Finally, Dr. Gabison discussed the use of metformin for medication-induced hyperglycemia, particularly with cancer therapies and glucocorticoids.
Subscribe to the Bi-monthly MCT2D Newsletter
We deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.